Skip to main content

AT SEA ON THE SEABOURN ODYSSEY

The open ocean.  Another day of mostly cuisine.  Slept late, but went to a Sommelier's Lunch in The Restaurant.  You can read the details.  Those dollars represent the cost of a bottle of wine if ordered with another meal.  The names are people on my table, all Australians.

Chief Sommelier Emi with the wines to be served at lunch.
Yellow-fin tuna, marinated artichoke and salad, with Veuve Cliques-Ponsardin Rose Champagne from Reims.
Foie gras ravioli with Cépe foam and accompanying Russian River Valley Williams Selyem 2014 Pinot Noir.
Louis Latour Corton-Charlemagne 2018 White Burgandy.
Napa Valley Silver Oak 2017 Cabernet Sauvignon.
The Cab in a decanter.
Slow roasted filet mignon.
Symington Family Quinta do Vesuvius Vintage 2017 Port for the closing Chocolate Variation and Raspberry Gelato.
It was a three-hour lunch, so dinner was only two soups and a salad.
Then on to the Let's Dance Party at the pool under starlight, and the stars were sparkling, the brightest I've seen in years.  You ask, what else did we do today?  Good question.  Not much.  I only walked 2440 steps.

-

Comments

Popular posts from this blog

A NEXT COVID SUBVARIANT?

By now most know that the Omicron BA.5 subvariant has become the dominant infectious agent, now accounting for more than 80% of all COVID-19 cases.  Very few are aware that a new one,   BA.4.6,  is sneaking in and steadily rising, now accounting for 13% of sequenced samples .  However, as BA.4.6 has emerged from BA.4, while there is uncertainty, the scientific sense is that the latest bivalent booster targeting BA.4 and BA.5 should also be effective for this next threat. One concern is that Evusheld--the only monoclonal antibody authorized for COVID prevention in immunocompromised individuals--is not effective against BA.4.6.  Here is a  reference  as to what this means.  A series of two injections is involved.  Evusheld was developed by British-Swedish company AstraZeneca, and is a t ixagevimab  co-packaged with  cilgavimab . More recently, Los Angeles County reported on  subvariant BA.2.75.2 . which Tony Fauci termed suspicio...

Part 3: OUR NEXT AROUND THE WORLD ODYSSEY

Before I get into my third, and final, part of this cruise series, let me start with some more newsworthy topics.  Thursday was my pandemic day for years.  Thus, every so often I return to bring you up to date on the latest developments.  All these  subvariants  derived from that Omicron variant, and each quickly became dominant, with slightly different symptoms.  One of these will shock you. There has been a significant decline in the lost of taste and smell.  From two-thirds of early patients to now only 10-20% show these symptoms. JN.1, now the dominant subvariant, results in mostly mild symptoms. However, once JN.1 infects some, there seem to be longer-lasting symptoms. Clearly, the latest booster helps prevent contracting Covid. A competing subvariant,  BA.2.86,  also known as Pirola , a month ago made a run, but JN.1 prevailed. No variant in particular, but research has shown that some of you will begin to  lose hair  for...

HONOLULU TO SEATTLE

The story of the day is Hurricane Milton, now a Category 4 at 145 MPH, with a track that has moved further south and the eye projected to make landfall just south of Sarasota.  Good news for Tampa, which is 73 miles north.  Milton will crash into Florida as a Category 4, and is huge, so a lot of problems can still be expected in Tampa Bay with storm surge.  If the eye had crossed into the state just north of Tampa, the damage would have been catastrophic.  Milton is a fast-moving storm, currently at 17 MPH, so as bad as the rainfall will be over Florida, again, a blessing.  The eye will make landfall around 10PM EDT today, and will move into the Atlantic Ocean north of Palm Bay Thursday morning. My first trip to Seattle was in June of 1962 just after I graduated from Stanford University.  Caught a bus. Was called the  Century 21 Exposition .  Also the Seattle World's Fair.  10 million joined me on a six-month run.  My first. These a...